Altimmune (ALT) Return on Equity (2011 - 2026)

Altimmune (ALT) has 16 years of Return on Equity data on file, last reported at 0.0% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.0%, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (up 1.0% YoY), and the FY2025 annual result was 0.0%, up 1.0% from the prior year.
• Return on Equity fell to 0.0% in Q1 2026 per ALT's latest filing, from 0.0% in the prior quarter.
• Over five years, Return on Equity peaked at 0.0% in Q4 2025 and troughed at 0.01% in Q4 2024.
• A 5-year average of 0.0% and a median of 0.0% in 2023 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2024 and 2025: Return on Equity decreased 1 bps in 2024, then rose 1 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.0% in 2022, then plunged by 517 bps to 0.0% in 2023, then sank by 94 bps to 0.01% in 2024, then surged by 98 bps to 0.0% in 2025, then plunged by 65 bps to 0.0% in 2026.
• Business Quant data shows ALT's Return on Equity at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.